The Skin in Systemic Scleroderma

Handbook of Systemic Autoimmune Diseases

Volumn 5, Issue , 2006, Pages 119-133

  Olski, Thorsten M ^a   Hunzelmann, Nicolas ^a   Krieg, Thomas ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649653595     PISSN: 15715078     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1571-5078(05)05010-5     Document Type: Review

References (67)

1. Aghassi D., Monoson T., and Braverman I. Reproducible measurements to quantify cutaneous involvement in scleroderma. Arch. Dermatol. 131 (1995) 1160
2. Airo P., Danieli E., Parrinello G., et al. Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results. Clin. Exp. Rheumatol. 22 (2004) 573
3. Akesson A., Fiori G., Krieg T., et al. Assessment of skin, joint, tendon and muscle involvement. Clin. Exp. Rheumatol. 21 3 Suppl. 29 (2003) S5
4. Akesson A., Hesselstrand R., Scheja A., et al. Longitudinal development of skin involvement and reliability of high frequency ultrasound in systemic sclerosis. Ann. Rheum. Dis. 63 (2004) 791
5. Balbir-Gurman A., Denton C.P., Nichols B., et al. Non-invasive measurement of biomechanical skin properties in systemic sclerosis. Ann. Rheum. Dis. 61 (2002) 237
6. Ballou S.P., Mackiewicz A., Lysikiewicz A., and Neuman M.R. Direct quantitation of skin elasticity in systemic sclerosis. J. Rheumatol. 17 (1990) 790
7. Basso M., Filaci G., Cutolo M., et al. Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. Ann. Ital. Med. Int. 16 (2001) 233
8. Bettoni L., Geri A., Airo P., et al. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin. Rheumatol. 21 (2002) 244
9. Binks M., Passweg J.R., Furst D., et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann. Rheum. Dis. 60 (2001) 577
10. Black C.M. Measurement of skin involvement in scleroderma. J. Rheumatol. 22 (1995) 1217
11. Bogoch E.R., and Gross D.K. Surgery of the hand in patients with systemic sclerosis: outcomes and considerations. J. Rheumatol. 32 (2005) 642
12. Brinckmann J., Neess C.M., Gaber Y., et al. Different pattern of collagen cross-links in two sclerotic skin diseases: lipodermatosclerosis and circumscribed scleroderma. J. Invest. Dermatol. 117 (2001) 269
13. Clements P.J., Hurwitz E.L., Wong W.K., et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum. 43 (2000) 2445
14. Clements P.J., Lachenbruch P.A., Seibold J.R., et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J. Rheumatol. 20 11 (1993) 1892-1896
15. Clements P., Lachenbruch P., Siebold J., et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J. Rheumatol. 22 (1995) 1281
16. Clements P.J., Seibold J.R., Furst D.E., et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned. Semin Arthritis Rheum. 33 4 (2004) 249-263
17. Chamberlain A.J., and Walker N.P. Successful palliation and significant remission of cutaneous calcinosis in CREST syndrome with carbon dioxide laser. Dermatol. Surg. 29 (2003) 968
18. Ciatti S., Varga J., and Greenbaum S.S. The 585 nm flashlamp-pumped pulsed dye laser for the treatment of telangiectases in patients with scleroderma. J. Am. Acad. Dermatol. 35 (1996) 487
19. Cutolo M., Pizzorni C., Tuccio M., et al. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatology (Oxford) 43 (2004) 719
20. Denton C.P., and Abraham D.J. Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr. Opin. Rheumatol. 13 (2001) 505
21. Dheda K., Lalloo U.G., Cassim B., et al. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin. Rheumatol. 23 (2004) 306
22. El-Mofty M., Mostafa W., El-Darouty M., et al. Different low doses of broad-band UVA in the treatment of morphea and systemic sclerosis. Photodermatol. Photoimmunol. Photomed. 20 (2004) 148
23. Enomoto D.N., Mekkes J.R., Bossuyt P.M., et al. Quantification of cutaneous sclerosis with a skin elasticity meter in patients with generalized scleroderma. J. Am. Acad. Dermatol. 35 (1996) 381
24. Furst D.E., Clements P.J., Steen V.D., et al. The modified Rodnan skin score is an accurate reflection of skin biopsythickness in systemic sclerosis. J. Rheumatol. 25 (1998) 84
25. Genth E. Evidence-based therapy of systemic sclerosis. J. Rheumatol. 60 (2001) 464
26. Herrick A., Rooney B., Finn J., et al. Lack of relationship between functional ability and skin score in patients with systemic sclerosis. J. Rheumatol. 28 (2001) 292
27. Hesselstrand R., Westergren-Thorsson G., Scheja A., et al. The association between changes in skin echogenicity and the fibroblast production of biglycan and versican in systemic sclerosis. Clin. Exp. Rheumatol. 20 (2002) 301
28. Hunzelmann N., Scharffetter Kochanek K., Hager C., et al. Management of localized scleroderma. Semin. Cutan. Med. Surg. 17 (1998) 34
29. Ioannidis J.P., Vlachoyiannopoulos P.G., Haidich A.B., et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am. J. Med. 118 (2005) 2
30. Ishikawa T., and Tamura T. Measurement of skin elastic properties with a new suction device (II): systemic sclerosis. J. Dermatol. 23 (1996) 165
31. Kawakami T., Ihn H., Xu W., et al. Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J. Invest. Dermatol. 110 (1998) 47
32. Kerscher M., Volkenandt M., Meurer M., et al. Treatment of localised scleroderma with PUVA bath photochemotherapy. Lancet 343 (1994) 1233
33. Klyscz T., Rassner G., Guckenberger G., et al. Biomechanical stimulation therapy. A novel physiotherapy method for systemic sclerosis. Adv. Exp. Med. Biol. 455 (1999) 309
34. Knight L.R., Smeathers J.E., Isdale A.H., et al. Evaluating the cutaneous involvement in scleroderma: torsional stiffness revisited. Rheumatology (Oxford) 40 (2001) 128
35. LeRoy E.C., Black C., Fleischmajer R., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 15 (1988) 202
36. Mayes M.D., Lacey Jr. J.V., Beebe-Dimmer J., et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 48 (2003) 2246
37. Mayes M.D. Scleroderma epidemiology. Rheum. Dis. Clin. North. Am. 29 (2003) 239
38. Medsger Jr. T.A., Masi AT., Rodnan G.P., et al. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann. Intern. Med. 75 (1971) 369
39. Moore T.L., Lunt M., McManus B., et al. Seventeen-point dermal ultrasound scoring system--a reliable measure of skin thickness in patients with systemic sclerosis. Rheumatology (Oxford) 42 (2003) 1559
40. Morita A., Kobayashi K., Isomura I., Tsuji T., and Krutmann J. Ultraviolet A1 (340-400 nm) phototherapy for scleroderma in systemic sclerosis. J. Am. Acad. Dermatol. 43 4 (2000) 670-674
41. Nives Parodi M., Castagneto C., Filaci G., et al. Plicometer skin test: a new technique for the evaluation of cutaneous involvement in systemic sclerosis. Br. J. Rheumatol. 36 (1997) 244
42. Pai B.S., Srinivas C.R., Sabitha L., et al. Efficacy of dexamethasone pulse therapy in progressive systemic sclerosis. Int. J. Dermatol. 34 (1995) 726
43. Pizzo G., Scardina G.A., and Messina P. Effects of a nonsurgical exercise program on the decreased mouth opening in patients with systemic scleroderma. Clin. Oral Investig. 7 (2003) 175
44. Pope J.E., Baron M., Bellamy N., et al. Variability of skin scores and clinical measurements in scleroderma. J. Rheumatol. 22 (1995) 1271
45. Pope J.E., Bellamy N., Seibold J.R., et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 44 (2001) 1351
46. Roch B., Wollina U., and Schroeder H.E. Long-term cyclosporin A in systemic sclerosis. J. Eur. Acad. Dermatol. Venereol. 18 (2004) 235
47. Rodnan G.P., Lipinski E., and Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum. 22 (1979) 130
48. Romanelli M., and Falanga V. Use of a durometer to measure the degree of skin induration in lipodermatosclerosis. J. Am. Acad. Dermatol. 29 (1993) 47
49. Sandqvist G., and Eklund M. Hand Mobility in Scleroderma (HAMIS) test: the reliability of a novel hand function test. Arthritis Care Res. 13 (2000) 369
50. Sandqvist G., and Eklund M. Validity of HAMIS: a test of hand mobility in scleroderma. Arthritis Care Res. 13 (2000) 382
51. Sandqvist G., Akesson A., and Eklund M. Evaluation of paraffin bath treatment in patients with systemic sclerosis. Disabil. Rehabil. 26 (2004) 981
52. Schuhfried O., Vacariu G., Lang T., et al. Thermographic parameters in the diagnosis of secondary Raynaud's phenomenon. Arch. Phys. Med. Rehabil. 81 (2000) 495
53. Seibold J.R. Clinical trials: types, design, and end-points. Curr. Opin. Rheumatol. 13 6 (2001) 512-515
54. Seyger M.M., van den Hoogen F.H., de Boo T., et al. Reliability of two methods to assess morphea: skin scoring and the use of a durometer. J. Am. Acad. Dermatol. 37 (1997) 793
55. Sharada B., Kumar A., Kakker R., et al. Intravenous dexamethasone pulse therapy in diffuse systemic sclerosis. A randomized placebo-controlled study. Rheumatol. Int. 14 (1994) 91
56. Silman A.J. Scleroderma and survival. Ann. Rheum. Dis. 50 (1991) 267
57. Simms R.W., and Korn J.H. Cytokine directed therapy in scleroderma: rationale, current status, and the future. Curr. Opin. Rheumatol. 14 (2002) 717
58. Steen V.D., and Medgser T.A. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 41 (1998) 1613
59. Steen V.D., and Medsger Jr. T.A. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum. 44 (2001) 2828
60. Sule S.D., and Wigley F.M. Treatment of scleroderma: an update. Expert Opin. Investig. Drugs 12 (2003) 471
61. Swartz R.D., Crofford L.J., Phan S.H., et al. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am. J. Med. 114 (2003) 563
62. Takei M., Shiraiwa H., Omata S., et al. A new tactile skin sensor for measuring skin hardness in patients with systemic sclerosis and autoimmune Raynaud's phenomenon. J. Int. Med. Res. 32 (2004) 222
63. Valentini G., D'Angelo S., Della Rossa A., et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann. Rheum. Dis. 60 (2001) 592
64. van der Slot A.J., Zuurmond A.M., Bardoel A.F., et al. Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. Biol. Chem. 278 (2003) 40967
65. van den Hoogen F.H., Boerbooms A.M., Swaak A.J., et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br. J. Rheumatol. 35 (1996) 364
66. von Kobyletzki G., Uhle A., Pieck C., et al. Acrosclerosis in patients with systemic sclerosis responds to low-dose UV-A1 phototherapy. Arch. Dermatol. 136 (2000) 275
67. Wigley F.M., and Sule S.D. Novel therapy in the treatment of scleroderma. Expert Opin. Investig. Drugs 10 (2001) 31